Kayne Anderson Rudnick Investment Management
SAGE

Kayne Anderson Rudnick Investment Management’s Sage Therapeutics SAGE Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20
Closed -$1K – 673
2022
Q1 		$1K Buy
+20
New +$752 ﹤0.01% 645

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's SAGE Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 20 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in SAGE in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 210 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 20 Sage Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Sage Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Sage Therapeutics position peaked at $1K in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.